PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29185103-14	2017	Aspirin, ticagrelor, and rosuvastatin all decreased TNF-alpha levels.	Rosuvastatin Calcium	25-37	tumor necrosis factor	Mus musculus	52-61	
30822620-0	2019	Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model.	Rosuvastatin Calcium	49-61	tumor necrosis factor	Mus musculus	82-85	
30822620-8	2019	RESULTS: Compared to the treatment with cilostazol alone, the combination treatment with rosuvastatin and cilostazol significantly reduced not only the levels of TNF in the sera but also macrophage infiltration in aortic lesions.	Rosuvastatin Calcium	89-101	tumor necrosis factor	Mus musculus	162-165	
30822620-10	2019	CONCLUSION: Rosuvastatin combined with cilostazol therapy can greatly improve the anti-inflammatory effect of monotherapies, resulting in reduced mortality of mice; thus, we propose the potential of use of this combination therapy as anti-TNF agent.	Rosuvastatin Calcium	12-24	tumor necrosis factor	Mus musculus	239-242	
16685407-9	2006	Rosuvastatin also inhibited increases in intestinal TNF-alpha protein and mRNA expression after DSS administration, respectively.	Rosuvastatin Calcium	0-12	tumor necrosis factor	Mus musculus	52-61	
28025996-11	2016	Rosuvastatin significantly decreased the expression levels of pro-inflammatry cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and transforming growth factor (TGF)-beta1.	Rosuvastatin Calcium	0-12	tumor necrosis factor	Mus musculus	97-130	
22382902-13	2012	Furthermore, treatment with rosuvastatin decreased the expression levels of TNF-alpha (group H, 65.19 +- 7.06 pg/ml; group L, 108.20 +- 5.28 pg/ml; group N, 239.34 +- 11.65 pg/ml) and IL-6 (group H, 14.33 +- 2.15 pg/ml; group L, 19.67 +- 3.04 pg/ml; group N, 40.39 +- 7.17 pg/ml).	Rosuvastatin Calcium	28-40	tumor necrosis factor	Mus musculus	76-85	
27316397-7	2016	CONCLUSION: AS attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through anti-inflammatory effect, resulting in down-regulation of TNF-alpha and IL-6, and further down-regulating IL-8 and MCP-1 expressions in aorta of WD fed ApoE(-/-) mice.	Rosuvastatin Calcium	97-109	tumor necrosis factor	Mus musculus	176-185	
23107893-7	2012	MCP-1 mRNA level was significantly increased in injured femoral arteries, and administration of irbesartan with rosuvastatin decreased the mRNA levels of MCP-1, TNFalpha, and IL-1beta, and increased PPARgamma mRNA expression.	Rosuvastatin Calcium	112-124	tumor necrosis factor	Mus musculus	161-169	
22613653-11	2012	RESULTS: Rosuvastatin reduced the number of total inflammatory cells, lymphocytes, macrophages, neutrophils, and eosinophils recruited into BALF, the levels of IL-4, IL-5, IL-13 and TNF-alpha in BALF, along with the histological mucus index (HMI) and GABAAR beta2 expression.	Rosuvastatin Calcium	9-21	tumor necrosis factor	Mus musculus	182-191	
12939225-9	2003	Furthermore, rosuvastatin specifically suppressed the expression of the inflammation parameters MCP-1 and TNF-alpha in the vessel wall and lowered plasma concentrations of serum amyloid A and fibrinogen, independent of its cholesterol-lowering effect.	Rosuvastatin Calcium	13-25	tumor necrosis factor	Mus musculus	106-115